Life Sciences Genitourinary Therapeutics & Diagnostics sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Genitourinary Therapeutics & Diagnostics
1.1 - About Life Sciences Genitourinary Therapeutics & Diagnostics sector
Companies in the Life Sciences Genitourinary Therapeutics & Diagnostics category develop and commercialize pharmacologic treatments, minimally invasive delivery platforms, and diagnostic technologies for urologic and renal disorders. They address conditions such as BPH, overactive bladder, incontinence, UTIs, kidney stones, and genitourinary cancers, improving detection, targeting therapy, and monitoring outcomes. Offerings span R&D pipelines, regulated manufacturing, and clinical evidence to support adoption across hospital and ambulatory care settings.
These vendors offer small‑molecule drugs and biologics for urologic indications, alongside targeted oncology therapeutics paired with companion diagnostics to guide treatment selection. Portfolios often include intravesical delivery platforms for localized therapy, urine‑based molecular assays and PSA testing to stratify risk, and urodynamics systems for objective bladder assessment. Many pair point‑of‑care urinalysis with digital symptom tracking and clinician dashboards, supported by clinical trial management, regulatory submissions, and market access programs typical of strategic buyers in this space.
They primarily serve hospitals and integrated delivery networks, outpatient urology practices, and diagnostic laboratories, with secondary focus on women’s health and nephrology centers. Outcomes include faster and more accurate diagnosis, reduced invasive procedures and readmissions, improved treatment response and adherence, and lower total cost of care. Their clinical validation, defensible IP, and scalable manufacturing enable expansion into new indications and geographies, supporting durable revenue growth and portfolio diversification.
2. Buyers in the Life Sciences Genitourinary Therapeutics & Diagnostics sector
2.1 Top strategic acquirers of Life Sciences Genitourinary Therapeutics & Diagnostics companies
Tela Bio
- Description: Provider of advanced soft-tissue reconstruction and hernia-repair medical devices, including reinforced tissue matrices and atraumatic adhesives that preserve patient anatomy, leverage natural healing responses, and minimize permanent synthetic material exposure.
- Key Products:
- OviTex Reinforced Tissue Matrix: Biologic-synthetic hybrid mesh delivering natural hernia repair, lowering recurrence rates and improving quality of life through tissue remodeling
- OviTex PRS Long-Term Resorbable: Reinforced matrix for plastic and reconstructive surgery offering bi-directional stretch, intuitive handling and diverse shapes for complex procedures
- OviTex IHR: Purpose-built inguinal hernia mesh providing reinforced strength with a lower synthetic footprint than traditional permanent mesh for durable, safer repairs
- LIQUIFIX Internal Adhesive: Strong, atraumatic adhesive for hernia mesh fixation eliminating penetrating tacks or sutures to enhance patient safety and comfort.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences Genitourinary Therapeutics & Diagnostics sector
M&A buyer group 1: Nephrology
Aurinia Pharmaceuticals
- Type: N/A
- Employees: ●●●●●
- Description: Provider of biopharmaceutical therapies for autoimmune diseases, offering LUPKYNIS, the first FDA-approved oral treatment for adult lupus nephritis, and advancing AUR200, a dual BAFF/APRIL inhibitor targeting B-cell activity to address high unmet medical needs.
- Key Products:
- LUPKYNIS (voclosporin): FDA-approved oral calcineurin-inhibitor immunosuppressant used with background therapy to treat adult patients with active lupus nephritis, rapidly reducing proteinuria and improving renal response
- AUR200 (aritinercept): investigational high-affinity dual BAFF/APRIL inhibitor that potently blocks B-cell proliferation and sustainably lowers immunoglobulins, aiming to treat multiple autoimmune diseases
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences Genitourinary Therapeutics & Diagnostics sector
3.1 - Buyout funds in the Life Sciences Genitourinary Therapeutics & Diagnostics sector
2.2 - Strategic buyer groups for Life Sciences Genitourinary Therapeutics & Diagnostics sector
4 - Top valuation comps for Life Sciences Genitourinary Therapeutics & Diagnostics companies
4.2 - Public trading comparable groups for Life Sciences Genitourinary Therapeutics & Diagnostics sector
Valuation benchmark group 1: Small-Molecule Pharmaceutical Manufacturing Companies
Eli Lilly
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and biotechnology solutions aimed at improving global health. Utilizes advanced scientific research and development to create treatments for various medical conditions, enhancing quality of life and addressing unmet clinical needs in diverse healthcare areas.
- Key Products:
- Insulin Access Programs: Solutions to provide accessible insulin treatments for diabetes management.
- Cancer Treatments: Medicines targeted at oncology to improve patient outcomes.
- Cardiovascular Treatments: Innovative treatments for heart-related conditions.
- Immunology: Solutions addressing autoimmune diseases and enhancing immune system health.
- Neuroscience: Medications to treat neurological disorders including Alzheimer's and schizophrenia.